Penny Stock Under Rs 5: Don't Miss Out on the Micro-Cap's Major News!
This groundbreaking technology has the potential for eliminating the need for painful injections.
Transgene Biotek Ltd has teamed up with NiedlFree Technologies Pvt Ltd. to revive and advance oral and nasal insulin delivery technology. This groundbreaking technology has the potential to revolutionize the way people with diabetes manage their condition, eliminating the need for painful injections.
In a recent canine insulin study, NiedlFree's oral insulin delivery technology achieved a relative bioavailability of over 90%, which is unprecedented. This means that the body absorbed more than 90% of the insulin administered orally, which is comparable to the absorption rate of injectable insulin.
NiedlFree has already initiated discussions with animal healthcare companies in Europe and the USA to monetize oral insulin in the pet care market. This market is estimated to be worth Rs. 16,000 crores in 2022, and Transgene believes that the successful launch of oral insulin in this segment could de-risk the outlook for future human clinical studies.
Transgene Biotek Ltd is developing and commercializing advanced technologies in Oncology, Oral Drug Delivery, and Bio-generics. The company employs a technology outsourcing model to mitigate risks and reduce costs. Its core focus lies in conducting pre-clinical and clinical trials to evaluate the safety and efficacy of these innovative technologies. Upon confirming the viability of a technology, Transgene Biotek Ltd. seeks patents to safeguard its intellectual property. Subsequently, it proceeds to bring these technologies to the market through licensing agreements or in-house manufacturing.
In 1999, Transgene Biotek Ltd. achieved a major milestone when it successfully sold its groundbreaking genetically engineered recombinant Hepatitis B vaccine technology and patented processes to the Serum Institute in Pune. This transaction demonstrated the company's strong track record of innovation and its ability to bring cutting-edge technologies to market.
Transgene Biotek Ltd.'s partnership with NiedlFree Technologies has the potential to revolutionize the way people with diabetes manage their condition. Oral insulin delivery could eliminate the need for painful injections and make it easier for people to adhere to their treatment plans. This could lead to improved health outcomes and a better quality of life for millions of people worldwide.
DSIJ’s ' Upstream Pick’ service recommends well researched contrarian stocks with high potential and high reward. If this interests you, do download the service details here.
Disclaimer: The article is for informational purposes only and not investment advice.